Embecta Corp. · NASDAQ:EMBC
Embecta — Wells Fargo Healthcare Conference 2022
13 slides from Embecta's conference presentation, Sep 8, 2022
Slide 1: Wells Fargo Healthcare Conference
Wells Fargo Healthcare Conference September 8, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements
Slide 3: Mission and Vision
Mission To develop and provide solutions that make life better for people living with diabetes Advance every day together Vision A life unlimited by diabetes 3
Slide 4: embecta is a Leader in the Global Marketplace
embecta is a Leader in the Global Marketplace Our strong core business reaches people with diabetes (PWD) around the world embecta by the numbers(1) #1 Globally ~7.6B ~30M Producer of Pen Units produced annually PWD reached annually Needles, Syringes & across Safety devices 3 world-class facilities
Slide 5: Our Business Provides a Financial Foundation for Growth
Our Business Provides a Financial Foundation for Growth Business model and a healthy balance sheet provide a strong core Stable, recurring, geographically- Healthy margin Strong cash flow Modest leverage Starting cash diversified profile generation at spin balance revenue base Vast majority of PWD B
Slide 6: Recap - Executive Summary of Q3 Fiscal Year 2022 Results
Recap - Executive Summary of Q3 Fiscal Year 2022 Results Resilient commercial performance amidst challenging macro environment, including supply chain and inflationary pressures, geo-political concerns, as well as certain COVID-19 disruptions Revenue of $291.1 million, down 1.3% on a reported basis;
Slide 7: embecta Near-Term Financial Profile and Targets
embecta Near-Term Financial Profile and Targets 1 Constant currency revenue growth CAGR expected to remain relatively flat over the near-term 2 Strong margins and cash flow generation allow embecta to employ “invest for growth” strategy 3 Acceleration of revenue growth profile expected to occur from
Slide 8: Strategic Investments to Accelerate our Long-term Growth Profile
Strategic Investments to Accelerate our Long-term Growth Profile Including commercial investments, next-gen products, and M&A Expand and penetrate Stronger R&D: M&A potential: through the core: We have opportunities to We can enter the T2D market We will seek partnerships drive growth in the core wi
Slide 9: Thank you
Thank you
Slide 10: Appendix
Appendix embecta’
Slide 11: Non-GAAP financial measures
Non-GAAP financial measures In evaluating our operating performance, we supplement the reporting of our financial information determined under GAAP with certain non-GAAP financial measures including (i) earnings before interest, taxes, depreciation, and amortization (“EBITDA”), (ii) adjusted EBITDA,
Slide 12: Adjusted Gross Margin Reconciliation
Adjusted Gross Margin Reconciliation Dollars in Millions, except percentages Three Months Ended Nine Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Revenue $291.1 $295.0 $854.9 $864.5 Cost of sales 88.2 92.4 256.9 274.3 Gross Profit 202.9 202.6 598.0 590.2 Gross Margin 69.7% 68
Slide 13: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Dollars in Millions Three Months Ended Nine Months Ended June 30, 2022 June 30, 2021 June 30, 2022 June 30, 2021 Net income $62.4 $104.7 $240.8 $317.9 Interest expense, net 19.5 — 24.4 — Income taxes 11.2 20.2 43.3 60.6 Depreciation and amortization 9.1 9.9 24.2 29.4 E